Science Explorer Back to mapMap
Institution · Vicore Pharma (Sweden)

Most cited papers from Vicore Pharma (Sweden)

What are the most cited papers from Vicore Pharma (Sweden)?

The most cited paper from Vicore Pharma (Sweden) is "Sintering of fat crystal networks in oil during post‐crystallization processes" (Dorota Johansson, Björn Bergenståhl, 1995), with 122 citations. Next come "Wetting of fat crystals by triglyceride oil and water. 1. The effect of additives" (72) and "Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial" (48).

Showing 26 of 26 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Sintering of fat crystal networks in oil during post‐crystallization processes Dorota Johansson, Björn Bergenståhl · Journal of the American Oil Chemists Society Aug 1995 122
2 Wetting of fat crystals by triglyceride oil and water. 1. The effect of additives Dorota Johansson, Björn Bergenståhl, Eva Lundgren · Journal of the American Oil Chemists Society Aug 1995 72
3 Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial Göran Tornling, Rohit Batta, Joanna C. Porter et al. · EClinicalMedicine Open access 25 Oct 2021 48
4 Water‐in‐triglyceride oil emulsions. Effect of fat crystals on stability Dorota Johansson, Björn Bergenståhl, Eva Lundgren · Journal of the American Oil Chemists Society Aug 1995 41
5 Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome Ilse C. Schrieks, Anna Nozza, Barbara Elisabeth Stähli et al. · Diabetes Care Open access 14 Jun 2018 40
6 Histopathological Studies on Kidneys from Patients Treated with Large John Falk, Gert Lindblad, Beatrice Westman · Transfusion Nov 1972 39
7 A Novel Polypeptide Derived From Human Lactoferrin in Sodium Hyaluronate Prevents Postsurgical Adhesion Formation in the Rat Elin Nilsson, Camilla Björn, Veronika Sjöstrand et al. · Annals of Surgery 23 Nov 2009 32
8 A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s Ariane L. Herrick, Rohit Batta, Kamilla Overbeck et al. · Lara D. Veeken Open access 27 Jul 2022 19
9 Weak gels of fat crystals in oils at low temperatures and their fractal nature Dorota Johansson · Journal of the American Oil Chemists Society Oct 1995 16
10 The influence of temperature on interactions and structures in semisolid fats Dorota Johansson · Journal of the American Oil Chemists Society Oct 1995 15
11 [PP.02.17] SUCCESSFUL COMPLETION OF A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE TRIAL FOR THE FIRST IN CLASS ANGIOTENSIN AT2-RECEPTOR AGONIST COMPOUND 21 U. Muscha Steckelings, Lena G.E. Mårtensson Lindblad, Anna Leisvuori et al. · Journal of Hypertension 30 Jul 2017 14
12 Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats Göran Tornling, Rohit Batta, Dan Salvail et al. · International Journal of Molecular Sciences Open access 19 Apr 2023 13
13 Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study Eva Lesén, Daniel Granfeldt, Anthony Berthon et al. · Journal of Cancer Open access 2019 12
14 Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome Barbara Elisabeth Stähli, Anna Nozza, Ilse C. Schrieks et al. · The Journal of Clinical Endocrinology & Metabolism Open access 6 Apr 2018 12
15 A digital therapy targeting anxiety in pulmonary fibrosis: A decentralized randomized controlled trial Joshua J. Solomon, Robert W. Hallowell, Cecilia Ganslandt et al. · Respirology Open access 3 Dec 2024 9
16 The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial Göran Tornling, Rohit Batta, Joanna C. Porter et al. · medRxiv PreprintOpen access 28 Jan 2021 9
17 Stoma Care Nurse Consultations Regarding Leakages and Peristomal Skin Complications During the First Year After Ostomy Creation: A Chart Review Eva I. Persson, Annabelle Forsmark, Gina Scheffel et al. · International Wound Journal Open access Apr 2025 6
18 Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist Erik Rein‐Hedin, Folke Sjöberg, Cecilia Ganslandt et al. · Clinical and Translational Science Open access Feb 2024 4
19 Respiratory Nurse Leadership Requires Increased Profile, Role Clarity and Stronger Career Pathways: Binational Delphi Consensus Process and TSANZ Position Statement Rebecca T. Disler, Catherine Buchan, Nikola Ncube et al. · Respirology Open access 4 Jul 2025 1
20 A110-06 Buloxibutid Stabilizes and Improves Lung Function in Idiopathic Pulmonary Fibrosis and Elevates Plasma Mmp-13, Linking AT2 Receptor Activation in Alveolar Epithelial Type 2 Cells to Resolution of Fibrosis J Raud, A Mousa, K Von Wachenfeldt et al. · American Journal of Respiratory and Critical Care Medicine May 2026 0
21 C103-23 Buloxibutid’s Efficacy in the Phase 2a Air IPF Trial: Comparative Analysis of Baseline Characteristics of Indian Versus World Cohorts K R Kirov, M Thillai, B Van Den Blink et al. · American Journal of Respiratory and Critical Care Medicine May 2026 0
22 D109-02 Microvascular Normalization and Fibrosis Regression by The Angiotensin II Type 2 Receptor Agonist Buloxibutid in Pulmonary Hypertension Associated With Interstitial Lung Disease J Raud, J Hofman, D Salvail et al. · American Journal of Respiratory and Critical Care Medicine May 2026 0
23 Beneficial effects of the AT 2 receptor agonist buloxibutid (C21) against acute alveolar epithelial cell inflammation during antiviral responses Franco Conforti, Joseph Bell, Robert A. Ridley et al. · ERJ Open Research Open access 22 Jan 2026 0
24 #3252 Anti-fibrotic profile of a next-generation AT2 receptor agonist in human fibrotic kidney tissue Johanna Gräns, Jimmie Hofman, Johan Raud · Nephrology Dialysis Transplantation Oct 2025 0
25 Investigation of the effect of the angiotensin II type 2 receptor (AT2R) agonist C21 on plasma NT-proBNP, a diagnostic biomarker, in subjects hospitalised with COVID-19 Rohit Batta, Göran Tornling, E. Rosendahl et al. · European Heart Journal Open access Oct 2022 0
26 Seven Days Treatment With the Angiotensin II Type 2 Receptor Agonist C21 in Hospitalized COVID-19 Patients: A Placebo-Controlled Randomized Phase 2 Trial Göran Tornling, Rohit Batta, Joanna C. Porter et al. · SSRN Electronic Journal PreprintOpen access 2021 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.